ArticleBone marrow transplantation2016
Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually.
Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
170 citing papers in PubMed, 6 syntheses or guidelines pooled it, 393 citations in OpenAlex.
- Effects of race and ethnicity on hematopoietic stem cell transplant outcomes in acute myeloid leukemia: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Prognostic value of sarcopenia in survivors of hematological malignances undergoing a hematopoietic stem cell transplantation: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Pooled it
- Critically ill allogenic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortality.Bone marrow transplantation · 2018Pooled it
- Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas.The Cochrane database of systematic reviews · 2017Pooled it
- Revisiting nutritional support for allogeneic hematologic stem cell transplantation-a systematic review.Bone marrow transplantation · 2017Pooled it
- National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Guideline
- Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial.Blood advances · 2023Trial
- Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial.Bone marrow transplantation · 2019Trial
- AlloHSCT in paediatric ALL and AML in complete remission: improvement over time impacted by accreditation?Bone marrow transplantation · 2019Trial
- Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors.Haematologica · 2019Trial
- High-dose chemotherapy and autotransplants for plasma cell myeloma in Jordan.Bone marrow transplantation · 2018Trial
- Return to Work After Hematopoietic Stem Cell Transplantation: A Longitudinal Analysis of Fatigue and Organ-Specific Chronic Graft-versus-Host Disease.Blood cell therapy · 2026Article
- Exploring the therapeutic effects of intensified immunosuppressive regimen for preengraftment syndrome after umbilical cord blood transplantation.Clinical and experimental medicine · 2025Article
- Feasibility of using saliva for Cytomegalovirus detection and genotyping in pediatric hematopoietic stem cell transplant recipients.Acta odontologica latinoamericana : AOL · 2025Article
- Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT.Bone marrow transplantation · 2025Article
- Transforming Medicine: Advances in Gene Therapy, Immunotherapy, and Targeted Cures.Current protein & peptide science · 2025Review
- Moving Toward Collecting High-Quality Umbilical Cord Blood: Application of Quality Control Circle.Journal of blood medicine · 2025Article
- Longitudinal assessment of oral intake adequacy and nutrition-impacted symptoms in patients undergoing allogeneic hematopoietic stem cell transplantation.Frontiers in nutrition · 2025Article
- Clinical impact of early microchimerism dynamics after transplantation with enhanced dual-conditioning regimen in hematological diseases.Frontiers in medicine · 2025Article
- HLA Diversity in Transylvanian Ethnic Groups: Consequences for Hematopoietic Cell Transplantation.Life (Basel, Switzerland) · 2024Article
110 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. Trends include: continued growth in transplant activity, more so in Eastern European countries than in the west; a continued increase in the use of haploidentical family donors (by 25%) and slower growth for unrelated donor HSCT. The use of cord blood as a stem cell source has decreased again in 2014. Main indications for HSCT were leukemias: 11 853 (33%; 96% allogeneic); lymphoid neoplasias; 20 802 (57%; 11% allogeneic); solid tumors; 1458 (4%; 3% allogeneic) and non-malignant disorders; 2203 (6%; 88% allogeneic). Changes in transplant activity include more allogeneic HSCT for AML in CR1, myeloproliferative neoplasm (MPN) and aplastic anemia and decreasing use in CLL; and more autologous HSCT for plasma cell disorders and in particular for amyloidosis. In addition, data on numbers of teams doing alternative donor transplants, allogeneic after autologous HSCT, autologous cord blood transplants are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.